{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,20]],"date-time":"2026-06-20T15:28:18Z","timestamp":1781969298584,"version":"3.54.5"},"reference-count":26,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,7,14]],"date-time":"2026-07-14T00:00:00Z","timestamp":1783987200000},"content-version":"am","delay-in-days":316,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jocn-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Clinical Neuroscience"],"published-print":{"date-parts":[[2025,9]]},"DOI":"10.1016\/j.jocn.2025.111462","type":"journal-article","created":{"date-parts":[[2025,7,15]],"date-time":"2025-07-15T17:31:24Z","timestamp":1752600684000},"page":"111462","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Efficacy and limitations of 180-day subcutaneous heparin therapy for cancer-associated ischemic stroke"],"prefix":"10.1016","volume":"139","author":[{"given":"Genpei","family":"Yamaura","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akihiro","family":"Nishimachi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kohei","family":"Harada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yosuke","family":"Miyaji","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuichi","family":"Higashiyama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroshi","family":"Doi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshiharu","family":"Nakae","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shigeru","family":"Koyano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naohisa","family":"Ueda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tatsu","family":"Nakano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yosuke","family":"Kudo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shigeki","family":"Yamaguchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mutsumi","family":"Yokoyama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fumiaki","family":"Tanaka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jocn.2025.111462_b0005","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1212\/WNL.0000000000000539","article-title":"Recurrent thromboembolic events after ischemic stroke in patients with cancer","volume":"83","author":"Navi","year":"2014","journal-title":"Neurology"},{"key":"10.1016\/j.jocn.2025.111462_b0010","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1159\/000491436","article-title":"Cancer-associated hypercoagulation increases the risk of early recurrent stroke in patients with active cancer","volume":"46","author":"Fujinami","year":"2018","journal-title":"Cerebrovasc. Dis."},{"key":"10.1016\/j.jocn.2025.111462_b0015","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/j.thromres.2021.08.016","article-title":"Therapeutic efficacy of heparin and direct factor Xa inhibitors in cancer-associated cryptogenic ischemic stroke with venous thromboembolism","volume":"206","author":"Yamaura","year":"2021","journal-title":"Thromb. Res."},{"key":"10.1016\/j.jocn.2025.111462_b0020","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1016\/j.jstrokecerebrovasdis.2018.10.012","article-title":"Subcutaneous heparin therapy for patients with cancer-associated stroke","volume":"28","author":"Kawano","year":"2019","journal-title":"J. Stroke Cerebrovasc. Dis."},{"key":"10.1016\/j.jocn.2025.111462_b0025","doi-asserted-by":"crossref","first-page":"2976","DOI":"10.1016\/j.jstrokecerebrovasdis.2017.07.029","article-title":"Treatment of cryptogenic stroke with active cancer with a new oral anticoagulant","volume":"26","author":"Nam","year":"2017","journal-title":"J. Stroke Cerebrovasc. Dis."},{"key":"10.1016\/j.jocn.2025.111462_b0030","doi-asserted-by":"crossref","DOI":"10.1155\/2015\/502089","article-title":"Comparison of enoxaparin and warfarin for secondary prevention of cancer-associated stroke","volume":"2015","author":"Jang","year":"2015","journal-title":"J. Oncol."},{"key":"10.1016\/j.jocn.2025.111462_b0035","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1001\/jamaneurol.2017.4211","article-title":"Enoxaparin vs aspirin in patients with cancer and ischemic stroke: the teach pilot randomized clinical trial","volume":"75","author":"Navi","year":"2018","journal-title":"JAMA Neurol."},{"key":"10.1016\/j.jocn.2025.111462_b0040","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1177\/17474930241239266","article-title":"Edoxaban for the treatment of hypercoagulability and cerebral thromboembolism associated with cancer: a randomized clinical trial of biomarker targets","volume":"19","author":"Chung","year":"2024","journal-title":"Int. J. Stroke"},{"key":"10.1016\/j.jocn.2025.111462_b0045","doi-asserted-by":"crossref","first-page":"e364","DOI":"10.1161\/STR.0000000000000375","article-title":"2021 guideline for the prevention of stroke in patients with stroke and transient ischemic attack: a guideline from the American Heart Association\/American Stroke Association","volume":"52","author":"Kleindorfer","year":"2021","journal-title":"Stroke"},{"key":"10.1016\/j.jocn.2025.111462_b0050","unstructured":"Committee for Stroke Guideline, The Japan Stroke Society. Japan Stroke Society Guideline 2021 for the Treatment of Stroke [Revised version 2023]. Tokyo: Kyowa Kikaku Ltd.; 2023. p. 244-6."},{"key":"10.1016\/j.jocn.2025.111462_b0055","doi-asserted-by":"crossref","first-page":"3063","DOI":"10.1200\/JCO.23.00294","article-title":"Venous thromboembolism prophylaxis and treatment in patients with cancer: ASCO guideline update","volume":"41","author":"Key","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.jocn.2025.111462_b0060","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1016\/j.annonc.2022.12.014","article-title":"Venous thromboembolism in cancer patients: ESMO Clinical Practice Guideline","volume":"34","author":"Falanga","year":"2023","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.jocn.2025.111462_b0065","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1182\/bloodadvances.2020003442","article-title":"American Society of Hematology 2021 guidelines for management of venous thromboembolism: prevention and treatment in patients with cancer","volume":"5","author":"Lyman","year":"2021","journal-title":"Blood Adv."},{"key":"10.1016\/j.jocn.2025.111462_b0070","doi-asserted-by":"crossref","first-page":"483","DOI":"10.6004\/jnccn.2024.0046","article-title":"Cancer-associated venous thromboembolic disease, version 2.2024, NCCN clinical practice guidelines in oncology","volume":"22","author":"Streiff","year":"2024","journal-title":"J. Natl. Compr. Canc. Netw."},{"key":"10.1016\/j.jocn.2025.111462_b0075","doi-asserted-by":"crossref","first-page":"5657","DOI":"10.1038\/s41467-024-50037-1","article-title":"Effectiveness and safety of continuous low-molecular-weight heparin versus switching to direct oral anticoagulants in cancer-associated venous thrombosis","volume":"15","author":"Kang","year":"2024","journal-title":"Nat. Commun."},{"key":"10.1016\/j.jocn.2025.111462_b0080","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1007\/s11239-024-02992-1","article-title":"Comparison of rivaroxaban and low molecular weight heparin in the treatment of cancer-associated venous thromboembolism: a swedish national population-based register study","volume":"57","author":"Linder","year":"2024","journal-title":"J. Thromb. Thrombolysis"},{"key":"10.1016\/j.jocn.2025.111462_b0085","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1161\/01.STR.24.1.35","article-title":"Classification of subtype of acute ischemic stroke. Definitions for use in a multicenter clinical trial. TOAST. Trial of Org 10172 in Acute Stroke Treatment","volume":"24","author":"Adams","year":"1993","journal-title":"Stroke"},{"key":"10.1016\/j.jocn.2025.111462_b0090","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1111\/j.1538-7836.2005.01204.x","article-title":"Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non-surgical patients","volume":"3","author":"Schulman","year":"2005","journal-title":"J. Thromb. Haemost."},{"key":"10.1016\/j.jocn.2025.111462_b0095","doi-asserted-by":"crossref","first-page":"1","DOI":"10.5853\/jos.2019.02278","article-title":"Cancer-related stroke: an emerging subtype of ischemic stroke with unique pathomechanisms","volume":"22","author":"Bang","year":"2020","journal-title":"J Stroke"},{"key":"10.1016\/j.jocn.2025.111462_b0100","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1191\/1358863x04vm566ra","article-title":"The heparins and cancer: review of clinical trials and biological properties","volume":"9","author":"Castelli","year":"2004","journal-title":"Vasc. Med."},{"key":"10.1016\/j.jocn.2025.111462_b0105","doi-asserted-by":"crossref","DOI":"10.3389\/fcvm.2022.951670","article-title":"Extracellular traps and the role in thrombosis","volume":"9","author":"Han","year":"2022","journal-title":"Front. Cardiovasc. Med."},{"key":"10.1016\/j.jocn.2025.111462_b0110","doi-asserted-by":"crossref","first-page":"164","DOI":"10.5853\/jos.2023.03279","article-title":"Cancer-associated stroke: thrombosis mechanism, diagnosis, outcome, and therapeutic strategies","volume":"26","author":"Heo","year":"2024","journal-title":"J Stroke"},{"key":"10.1016\/j.jocn.2025.111462_b0115","doi-asserted-by":"crossref","DOI":"10.3389\/fneur.2022.868137","article-title":"Post-treatment plasma D-dimer levels are associated with short-term outcomes in patients with cancer-associated stroke","volume":"13","author":"Nakajima","year":"2022","journal-title":"Front. Neurol."},{"key":"10.1016\/j.jocn.2025.111462_b0120","doi-asserted-by":"crossref","first-page":"77","DOI":"10.5853\/jos.2016.00570","article-title":"Hypercoagulability and mortality of patients with stroke and active cancer: the OASIS-cancer study","volume":"19","author":"Lee","year":"2019","journal-title":"J Stroke"},{"key":"10.1016\/j.jocn.2025.111462_b0125","doi-asserted-by":"crossref","first-page":"e393","DOI":"10.1212\/WNL.0000000000200601","article-title":"In-hospital outcomes and recurrence of acute ischemic stroke in patients with solid organ malignancy","volume":"99","author":"Garg","year":"2022","journal-title":"Neurology"},{"key":"10.1016\/j.jocn.2025.111462_b0130","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1191\/0269216305pm1008oa","article-title":"Is long-term low-molecular-weight heparin acceptable to palliative care patients in the treatment of cancer related venous thromboembolism?","volume":"19","author":"Noble","year":"2005","journal-title":"A qualitative study Palliat Med"}],"container-title":["Journal of Clinical Neuroscience"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0967586825004357?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0967586825004357?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,6]],"date-time":"2025-09-06T18:38:49Z","timestamp":1757183929000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0967586825004357"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9]]},"references-count":26,"alternative-id":["S0967586825004357"],"URL":"https:\/\/doi.org\/10.1016\/j.jocn.2025.111462","relation":{},"ISSN":["0967-5868"],"issn-type":[{"value":"0967-5868","type":"print"}],"subject":[],"published":{"date-parts":[[2025,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Efficacy and limitations of 180-day subcutaneous heparin therapy for cancer-associated ischemic stroke","name":"articletitle","label":"Article Title"},{"value":"Journal of Clinical Neuroscience","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jocn.2025.111462","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"111462"}}